iBio to Participate in the 8th Annual Evercore Healthcare Conference
Rhea-AI Summary
iBio (NASDAQ: IBIO) will participate in the 8th Annual Evercore Healthcare Conference in Miami, December 2–4, 2025. Martin Brenner, DVM, Ph.D., CEO and Chief Scientific Officer, will appear in a fireside chat on Thursday, December 4, 2025 at 8:45 a.m. ET to discuss iBio’s progression of its next‑generation obesity pipeline toward clinical development and recent non‑human primate data for IBIO‑610 presented at ObesityWeek 2025.
Felipe Duran, CFO, will be available for one‑on‑one meetings during the conference. A livestream will be available and a replay link will be posted on the company’s Investor website.
Positive
- None.
Negative
- None.
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the 8th Annual Evercore Healthcare Conference, taking place December 2–4, 2025, in Miami.
Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will participate in a fireside chat on Thursday, December 4, 2025, at 8:45 a.m. ET. Dr. Brenner will outline iBio’s ongoing efforts to move its next-generation obesity pipeline into clinical development, emphasizing the promising new non-human primate data for IBIO-610, a potential first-in-class Activin E antibody, presented at ObesityWeek® 2025.
Felipe Duran, iBio’s Chief Financial Officer, will be available with Dr. Brenner for one-on-one meetings during the conference.
A livestream of the event can be accessed here. A link to access the replay will be posted on the Investor section of the iBio website.
About iBio, Inc.
iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com or follow us on LinkedIn.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the Company’s continued development in becoming a clinical-stage biotechnology company; its progress across its next generation obesity pipeline; regarding the therapeutic potential of Activin E as a target for cardiometabolic disorders and obesity; IBIO-610 preclinical data predicting human half-life of up to 100 days, suggesting the potential for dosing as infrequently as twice per year; participation in the 8th Annual Evercore Healthcare Conference, taking place December 2-5, 2025 in Miami;. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of the Company to commence clinical trials; the ability of the Company’s antibody programs to complement existing obesity therapies and create long-term value through innovation and scientific leadership; Activin E being a successful target for cardiometabolic disorders and obesity and iBio’s antibody to induce fat-selective weight loss and offer protection against obesity and cardiometabolic disease; iBio’s ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio’s ability to promote or commercialize its product candidates for specific indications; acceptance of iBio’s product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio’s filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2025 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Corporate Contact:
iBio, Inc.
Investor Relations
ir@ibioinc.com
Media Contacts:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
FAQ
When will iBio (IBIO) present at the Evercore Healthcare Conference in 2025?
Who from iBio (IBIO) will speak at the Evercore Healthcare Conference on December 4, 2025?
What topics will iBio (IBIO) cover in the December 4, 2025 fireside chat?
Will there be a livestream or replay of iBio’s (IBIO) Evercore presentation?
What is IBIO‑610 and where were its preclinical results presented?
Can investors request one‑on‑one meetings with iBio (IBIO) management at Evercore December 2025?
